Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-01

Clinical Trial Update: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of eculizumab in adult patients with plasma therapy-resistant atypical hemolytic uremic syndrome completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SOLIRIS (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Atypical Hemolytic Uremic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2014-12-01